Ge Healthcare Technologies Inc - GEHC STOCK NEWS

GE HealthCare (GEHC) has unveiled Freelium, a revolutionary sealed magnet platform for MRI systems that uses less than 1% of helium compared to conventional magnet technology. The platform builds upon GE HealthCare's lightweight intelligent magnet technology, which has achieved over 2,000 installations worldwide since 2020.

Key features of Freelium include:

• Operates without additional cooling and power requirements
• Intelligent sensor technology for remote monitoring and automated magnet protection
• Compatibility with AI-enabled solutions
• Enhanced transportability to areas with helium access

The technology aims to maintain high imaging performance while supporting sustainability goals. Through its intelligent magnet technology and Continuum upgrades, GE HealthCare has already saved approximately 3 million liters of helium.

GE HealthCare (GEHC) has begun administering the first patient doses of Flyrcado™ (flurpiridaz F 18), its newly FDA-approved PET radiotracer, at early adopter sites across the United States. This first-of-its-kind unit dose PET myocardial perfusion imaging (MPI) agent shows higher diagnostic efficacy compared to current SPECT MPI for detecting coronary artery disease (CAD).

With a significant 109-minute half-life, Flyrcado eliminates the need for onsite production and enables wider distribution. The company expects to reach nearly all existing cardiac PET centers by end of 2025, with full commercialization anticipated in Q2 2025. Houston Methodist Hospital and UW Health University Hospital are among the first adopters.

GE HealthCare has filed for CMS pass-through status to secure procedural codes and reimbursement rates, enhancing accessibility. The product enables exercise stress testing with cardiac PET imaging, offering new capabilities for CAD evaluation among the approximately 6 million annual MPI procedures in the US.

GE HealthCare (GEHC) reported strong Q4 2024 financial results with revenue growth of 2% year-over-year to $5.3 billion. The company achieved significant margin improvements, with net income margin rising to 13.5% from 7.7% and adjusted EBIT margin increasing to 18.7% from 16.1%.

For full-year 2024, GEHC posted revenue of $19.7 billion, up 1% year-over-year, with net income of $2.0 billion versus $1.6 billion in 2023. The company's performance was driven by strong demand in Advanced Visualization Solutions and Pharmaceutical Diagnostics, particularly in the U.S. market, though partially offset by softness in China.

Looking ahead to 2025, GEHC provided guidance including organic revenue growth of 2-3%, adjusted EBIT margin of 16.7-16.8%, and adjusted EPS of $4.61-$4.75. The company also announced strategic partnerships with Sutter Health and Nuffield Health, while investing $138 million in its Cork, Ireland manufacturing facility.

GE HealthCare (Nasdaq: GEHC) has announced its management team's upcoming participation at Citi's 2025 Medtech and Life Sciences Access Day. The presentation is scheduled for February 27, 2025, at 2:15 PM CT / 3:15 PM ET. Investors and interested parties can access the webcast of this event through GE HealthCare's investor relations website at investor.gehealthcare.com/news-events/events during the scheduled time.

GE HealthCare (GEHC) announced a $138 million investment to expand its contrast media manufacturing facility in Cork, Ireland. The new 3000m2 state-of-the-art facility will increase production capacity by 25 million patient doses per year by the end of 2027.

The expansion aims to address the growing global demand for iodine-based contrast media, which is expected to double in the next decade. The investment includes solution preparation vessels, powder handling systems, a new filling line, and autoclaves with advanced automation systems.

The Cork facility, along with sites in Shanghai and Oslo, supplied over 100 million patient doses of contrast media in 2024. Construction will begin in February 2025, creating over 250 construction roles.

GE HealthCare (GEHC) has achieved a significant milestone by being named to the 2025 Fortune World's Most Admired Companies™ list for the first time since becoming an independent company. The recognition spans multiple categories, including management quality, products and services, innovation, investment value, and environmental responsibility.

The company's inclusion on this prestigious list reflects its successful implementation of the precision care strategy and its commitment to improving clinical workflows and patient outcomes. With 51,000 global colleagues, GE HealthCare continues to build upon its 125-year legacy of innovation in healthcare.

The ranking, considered the 'gold standard' for employee-centric companies, requires companies to score in the top half of their industry survey to be listed. This achievement validates GE HealthCare's entrepreneurial and inclusive culture, which focuses on delivering innovative healthcare solutions worldwide.

GE HealthCare (GEHC) has received FDA 510(k) clearance for its updated Voluson Expert Series ultrasound systems. The new series, comprising Voluson Expert 22, 20, and 18, combines high-resolution imaging with AI-powered features and automation tools designed for women's healthcare.

The systems feature Lyric Architecture for detailed imaging and include enhanced AI tools like SonoLyst for automated annotations and measurements during 11-14 week anatomical exams. Notable improvements include Graphicflow for blood flow visualization and upgraded tools like SonoPelvicFloor3.0, which reduces pelvic floor measurement exam time by 80%, and SonoAVCfollicle2.0 for improved follicle detection.

This development addresses a critical healthcare need, as approximately 30,000 to 50,000 women in the United States experience complex, high-risk pregnancies annually. The systems will be showcased at the SMFM 2025 Pregnancy Meeting in Denver.

UCSF and GE HealthCare have launched a Care Innovation Hub, a joint research collaboration focusing on three key areas: advanced medical imaging accessibility, non-invasive diagnosis of neurological diseases, and precision oncology. The partnership combines UCSF's clinical expertise with GE HealthCare's technical knowledge to develop innovative healthcare solutions.

The collaboration aims to develop automated imaging methods, including patient-specific MRI techniques that adapt in real-time, explore connections between various brain conditions including Alzheimer's disease, and advance quantitative imaging methods for monitoring patient response to radiopharmaceutical therapies (RPTs).

The research will be conducted at UCSF facilities in the San Francisco Bay Area, with goals of improving diagnosis, treatment, hospital operations, and ensuring more equitable access to care.

Sutter Health and GE HealthCare (GEHC) have announced a seven-year strategic Care Alliance partnership, representing one of GE HealthCare's largest enterprise collaborations. The partnership aims to enhance imaging services across Sutter's 300+ facilities serving 3.5 million patients in California.

The alliance focuses on implementing advanced AI-powered imaging technology including PET/CT, SPECT/CT, MRI, CT, X-ray, nuclear medicine, and ultrasound systems. Key technologies include GE HealthCare's Omni Legend PET/CT, StarGuide SPECT/CT, and Vscan Air™ SL ultrasound with Caption AI™ software.

The collaboration will support Sutter's expansion plans, including new care sites across Northern California and specialized centers for heart, vascular, cancer, and neuroscience care. The partnership includes workforce development programs through Sutter Health University, focusing on training technologists, nurses, and physicians while promoting diversity in healthcare staffing.